Abstract 1576P
Background
In Italy, progress in lung cancer mortality in men is not paralleled by similar trends in women, though exposure to tobacco smoking is well known to be the key driver of lung cancer incidence and mortality. This study aimed to compare recent trends in lung cancer mortality rates in Italian men and women.
Methods
Mortality data for 2003-2019 were retrieved from death certificates compiled by the Italian National Institute for Statistics. These data were used to compute, separately in men and women, age-standardized mortality rates (/105/year) for lung cancer (ICD-10: C33-C34.9). Furthermore, we estimated the absolute number of prevented lung cancer deaths in 2007-2019 in Italy, as the difference between the observed and expected (based on the 2003-2006 mortality rates) number of lung cancer deaths. Data on the prevalence of tobacco smoking in men and women were collected from national surveys.
Results
In Italian men, the use of tobacco smoking strongly declined from 60% in the 1960s to 27.7% in 2021, whereas it tended to increase in women – particularly in the two last decades from 16.6% in 2004 to 20.7% in 2021. In men, a decline from 2007 to 2019 in lung cancer mortality rates was documented in all geographic areas (e.g., from 121.2/105 to 92.6/105 in northern Italy; and from 98.5/105 to 91.4/105 in southern Italy). Conversely, upward trends were registered for women: from 30.3/105 to 33.8/105 in the North; and from 16.3/105 to 20.3/105 in the South. From 2007 to 2019, there was an 18.7% reduction in the expected number of lung cancer deaths in men (-73.397) and an increase of 16.0% in expected deaths in women (+16.036).
Conclusions
Study findings strengthen the persistent need for tailoring interventions to reduce smoking among females to invert lung cancer mortality trends in Italian women.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Italian Ministry of Health, Ricerca Corrente IRCCS CRO, Aviano.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10